|
⚲
|
| Keyboard |
| Southpoint Capital Advisors LP
✚
|
|
|---|---|
| CRD # | 161754 |
| SEC # | 801-74264 |
| CIK # | 0001319998, 0001378377 |
| AUM | 6,626.2 M (2026-03-31) |
| Employees | 17 (65% Investors, 0% Brokers) |
| Phone | 212-692-6350 |
| Address | 1114 Avenue of The Americas New York, NY 10036 |
| Source | [IAPD] [EDGAR] [Website] |
| Total AUM ($B) |
|---|
| Sector | Form 13F Holdings | Value ($B) | |
|---|---|---|---|
| Circle Internet Group Inc | 0.3 | ||
| Zoetis Inc | 0.3 | ||
| Illumina Inc | 0.3 | ||
| Alcon Inc | 0.3 | ||
| Equinix Inc | 0.2 | ||
| Henry Schein Inc | 0.2 | ||
| Uber Technologies Inc | 0.2 | ||
| Microsoft Corp | 0.2 | ||
| Thermo Fisher Scientific Inc | 0.2 | ||
| Spotify Technology Sa | 0.2 | ||
| View All | |||
| Holdings by Sector ($B) |
|---|
| Type | Form D Funds | Date | Sold | AUM |
|---|---|---|---|---|
| HF | Southpoint Master Fund LP | [2018-03-28] | 1,646.7 M | 6,626.2 M |
| Filed 2025-04-08 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Minimum $1,000,000 · Remaining Indefinite · Duration More than one year · Net Assets Decline to Disclose | ||||
| HF | Southpoint Master Fund LP | [2012-02-15] | 1,646.7 M | 3,865.8 M |
| Filed 2025-04-08 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Minimum $1,000,000 · Remaining Indefinite · Duration More than one year · Net Assets Decline to Disclose | ||||
| AUM Breakdown | Accounts | AUM ($B) |
|---|---|---|
| By Client Type | ||
| (a) Individuals (other than high net worth individuals) | 0 | 0.0 |
| (b) Individuals (high net worth individuals) | 0 | 0.0 |
| (c) Banking or thrift institutions | 0 | 0.0 |
| (d) Investment companies | 0 | 0.0 |
| (e) Business development companies | 0 | 0.0 |
| (f) Pooled investment vehicles | 2 | 6.6 |
| (g) Pension and profit sharing plans | 0 | 0.0 |
| (h) Charitable organizations | 0 | 0.0 |
| (i) State or municipal government entities | 0 | 0.0 |
| (j) Other investment advisers | 0 | 0.0 |
| (k) Insurance companies | 0 | 0.0 |
| (l) Sovereign wealth funds and foreign official institutions | 0 | 0.0 |
| (m) Corporations or other businesses not listed above | 0 | 0.0 |
| (n) Other | 0 | 0.0 |
| Total | 2 | 6.6 |
| By Discretionary | ||
| Discretionary | 2 | 6.6 |
| Non-Discretionary | 0 | 0.0 |
| Total | 2 | 6.6 |
| By Non-United States Persons | ||
| Non-United States Persons | 0.4 | |
| United States Persons | 6.2 | |
| Total | 2 | 6.6 |
| Form D Directors | Role | # Filings | # Firms | 2011 - 2026 |
|---|---|---|---|---|
| Darren Stainrod | Director | 145 | 26 | |
| Laren Gillespie | Director | 119 | 24 | |
| Benjamin Carter | Director | 10 | 3 | |
| Southpoint Capital Advisors LP | Promoter | 4 | 2 | |
| John Clark II | Director | 4 | 2 | |
| Southpoint Capital Advisors LLC | Promoter | 2 | 2 | |
| Anthony Buffalano III | Promoter | 2 | 2 |
| EDGAR Form | CIK | 2011 - 2026 |
|---|---|---|
| 13F-HR | [0001319998] | |
| 3 | [0001319998] | |
| 4 | [0001319998] | |
| SC 13G | [0001319998] | |
| 13F-NT | [0001378377] | |
| 3 | [0001378377] | |
| 4 | [0001378377] |
| Firm Profile (Form ADV) | |
|---|---|
| Discretionary AUM | $0.3B |
| Serves | Institutional |
| Fund Types | Hedge Fund |
| LEI | 0YPU8TSIANKX6T56SD94 |
| Form 3/4/5 Subject | 2011 - 2026 |
|---|---|
| Southpoint Capital Advisors LLC | |
| Southpoint GP LP | |
| Clark John Smith II | |
| Fennec Pharmaceuticals Inc | |
| Southpoint Capital Advisors LP | |
| Southpoint GP LLC |
| Insider Transaction (Form 3/4/5) | Date | Action | Shares | Price | Value ($) |
|---|---|---|---|---|---|
|
Fennec Pharmaceuticals Inc FENC
Common Stock
|
2025-12-24 | Sell | 1,000,000 | $7.50 | 7,500,000 |
|
Fennec Pharmaceuticals Inc FENC
Common Stock
|
2025-11-18 | Sell | 19,341 | $8.79 | 170,007 |
|
Fennec Pharmaceuticals Inc FENC
Common Stock
|
2025-11-17 | Sell | 85,918 | $8.79 | 755,219 |
|
Fennec Pharmaceuticals Inc FENC
Common Stock
|
2025-11-14 | Sell | 160,100 | $8.00 | 1,280,800 |
|
Fennec Pharmaceuticals Inc FENC
Common Stock
|
2025-10-09 | Sell | 20,609 | $9.35 | 192,694 |
|
Fennec Pharmaceuticals Inc FENC
Common Stock
|
2025-10-08 | Sell | 19,605 | $9.47 | 185,659 |
|
Fennec Pharmaceuticals Inc FENC
Common Stock
|
2025-10-07 | Sell | 26,900 | $9.59 | 257,971 |
|
Fennec Pharmaceuticals Inc FENC
Common Stock
|
2020-05-04 | Buy | 80,000 | $6.25 | 500,000 |
| Comparable Firms | State | AUM |
|---|---|---|
|
Atom Investors LP
✚
|
TX | 6,826.9 M |
|
Abbey Capital Limited
✚
|
6,815.7 M | |
|
Glazer Capital LLC
✚
|
NY | 6,814.6 M |
|
Laurion Capital Management LP
✚
|
NY | 6,764.0 M |
|
Trutino Capital Management LLC
✚
|
NY | 6,715.6 M |
|
Trian Fund Management LP
✚
|
NY | 6,714.4 M |
|
North of South Capital LLP
✚
|
6,696.7 M | |
|
Quantbot Technologies LP
✚
|
NY | 6,650.7 M |
|
K2/D&S Management Co LLC
✚
|
CT | 6,534.8 M |
|
Foxhaven Asset Management LP
✚
|
VA | 6,504.3 M |